TriangleDISEASE & TREATMENT SETTING
Malignant Peritoneal Neoplasm
Source-derived catalogue. This is not a treatment recommendation or a personalised trial match.
Exact scope
Malignant Peritoneal Neoplasm
- Source population
- Not part of this definition
- Disease extent
- Not part of this definition
- Treatment line
- Not part of this definition
- Stage
- Not part of this definition
- Resectability
- Not part of this definition
Biomarkers, prior therapy and derivation
- molecular
- prior therapy
- derivation status
- source-attested
- derivation note
- Added because the terminology and the registry both attest it: an NCIt neoplasm concept named by 12 acquired study condition(s). It is absent from the NCI treatment-topic directory, which is not an exhaustive cancer inventory.
- source wording
- Source null
21 more-specific settings
Elahere: peritoneal cancer after prior therapy →Lynparza: advanced peritoneal cancer with BRCA stated without a specific alteration (first-line) →Lifyorli: peritoneal cancer after prior therapy →Rubraca: recurrent peritoneal cancer with BRCA mutation (maintenance) →Vegzelma: recurrent peritoneal cancer →ZEJULA: advanced peritoneal cancer (first-line) →ALYMSYS: recurrent peritoneal cancer →ZEJULA: advanced peritoneal cancer with BRCA mutation (first-line) →JOBEVNE: peritoneal cancer after prior therapy →Zirabev: peritoneal cancer after prior therapy →MVASI: recurrent peritoneal cancer →Lynparza: advanced peritoneal cancer (first-line) →Lynparza: recurrent peritoneal cancer with BRCA stated without a specific alteration (maintenance) →Rubraca: recurrent peritoneal cancer with BRCA stated without a specific alteration, BRCA mutation (maintenance) →ZEJULA: recurrent peritoneal cancer with BRCA stated without a specific alteration (maintenance) →Avastin: recurrent peritoneal cancer →JOBEVNE: recurrent peritoneal cancer →Zirabev: recurrent peritoneal cancer →Avastin: peritoneal cancer after prior therapy →MVASI: peritoneal cancer after prior therapy →Vegzelma: peritoneal cancer after prior therapy →
Study evidence for this setting
Letrozole in Patients With Ovarian Tumors
Allogeneic Natural Killer Cells in Patients With Recurrent Ovarian Cancer, Fallopian Tube, and Primary Peritoneal Cancer
Outcomes From Home in Patients Recovering From Major Gynecologic Cancer Surgery: Measuring Symptoms and Health-related Quality of Life
Erlotinib Hydrochloride in Treating Patients With Malignant Peritoneal Mesothelioma
A Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2)
Phase 3 Study of Rucaparib as Switch Maintenance After Platinum in Relapsed High Grade Serous or Endometrioid Ovarian Cancer (ARIEL3)
HIPEC for Peritoneal Carcinomatosis
αDC1 Vaccine + Chemokine Modulatory Regimen (CKM) as Adjuvant Treatment of Peritoneal Surface Malignancies
Pembrolizumab in Treating Patients With Malignant Mesothelioma
Methoxyamine, Cisplatin, and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors or Mesothelioma That Cannot Be Removed by Surgery or Mesothelioma That Is Refractor
Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer
ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients
CAR T Cells in Mesothelin Expressing Cancers
Trial of Trientine Plus Pegylated Liposomal Doxorubicin and Carboplatin in Epithelial Ovarian Cancer
A Study of Mirvetuximab Soravtansine vs. Investigator's Choice (IC) of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian
A Study of Mirvetuximab Soravtansine in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Ex
A Study of NM21-1480 in Adult Patients With Advanced Solid Tumors
Intravenous and Intraperitoneal Paclitaxel and Oral Nilotinib for Peritoneal Carcinomatosis
Indication-specific source history
2022-11-14 · Elahere (mirvetuximab soravtansine-gynx) · accelerated approval
- release id
- clinical-indications-draft-1
- disease state id
- ds-malignant-peritoneal-neoplasm
- event id
- fda-84802b5888e8d269
- event date
- 2022-11-14
- event kind
- accelerated-approval
- drug or regimen
- Elahere (mirvetuximab soravtansine-gynx)
- source indication text
- Adult patients with folate receptor-alpha (FRα) positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received one to three prior systemic treatment regimens. Select patients for therapy based on an FDA-approved test
- match phrase
- peritoneal cancer
- match status
- candidate
- status category
- verified_clinical_benefit
- has date discrepancy
- 0
- source collection
- fda-status-row
- source key
- fda-aa-1475f115c251cd55b4eb
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
2024-03-22 · Elahere (mirvetuximab soravtansine-gynx) · traditional approval
- release id
- clinical-indications-draft-1
- disease state id
- ds-malignant-peritoneal-neoplasm
- event id
- fda-c556731c3834688f
- event date
- 2024-03-22
- event kind
- traditional-approval
- drug or regimen
- Elahere (mirvetuximab soravtansine-gynx)
- source indication text
- Adult patients with folate receptor-alpha (FRα) positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received one to three prior systemic treatment regimens. Select patients for therapy based on an FDA-approved test
- match phrase
- peritoneal cancer
- match status
- candidate
- status category
- verified_clinical_benefit
- has date discrepancy
- 0
- source collection
- fda-status-row
- source key
- fda-aa-1475f115c251cd55b4eb
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
2026-03-25 · relacorilant with nab-paclitaxel · approval notification
- release id
- clinical-indications-draft-1
- disease state id
- ds-malignant-peritoneal-neoplasm
- event id
- notice-3356ee834d8e6e3b
- event date
- 2026-03-25
- event kind
- approval-notification
- drug or regimen
- relacorilant with nab-paclitaxel
- source indication text
- FDA approved relacorilant, a glucocorticoid receptor antagonist, in combination with nab-paclitaxel for the treatment of adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior systemic treatment regimens, at least one of which included bevacizumab.
- match phrase
- peritoneal cancer
- match status
- candidate
- status category
- Source null
- has date discrepancy
- 0
- source collection
- fda-approval-notice
- source key
- fda-d4ea94bc27b96b36
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
Source relationships and population-mapping limitations
- bindings
- release id
- clinical-indications-draft-1
- disease state id
- ds-malignant-peritoneal-neoplasm
- binding id
- ncit-C3538
- source collection
- ncit-concept
- source key
- C3538
- source excerpt
- Source null
- match status
- exact
- match note
- Source null
- recorded at
- 2026-09-10T00:00:00Z
- mappings
Download this complete draft source relationship record →
Preserved source evidence · Not medical advice